{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T09:12:32Z","timestamp":1788599552211,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-162243"],"award-info":[{"award-number":["PJT-162243"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN-148465"],"award-info":[{"award-number":["FDN-148465"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000109","name":"Prostate Cancer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004111","name":"Leading Edge Endowment Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015803","name":"British Columbia Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bmc.2026.118779","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:42:50Z","timestamp":1786981370000},"page":"118779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PSMA binding of carbamate-containing peptidomimetics influenced by side chain length and stereocenter configuration in preclinical prostate cancer model"],"prefix":"10.1016","volume":"142","author":[{"given":"\u00c1ron","family":"Roxin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Merkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Colpo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Shyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"B\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118779_bb0005","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2967\/jnumed.117.203877","article-title":"A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies","volume":"59","author":"O\u2019Keefe","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bmc.2026.118779_bb0010","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jcb.10661","article-title":"Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer","volume":"91","author":"Ghosh","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.bmc.2026.118779_bb0015","series-title":"Management of Prostate Cancer","first-page":"609","article-title":"Biology of PSMA As a Diagnostic and Therapeutic Target","author":"Chang","year":"2004"},{"key":"10.1016\/j.bmc.2026.118779_bb0020","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/409179","article-title":"A comparison of the biological features of prostate cancer with (PSA+, PSMA+) profile according to RKIP","volume":"2013","author":"Ben Jemaa","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.bmc.2026.118779_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-22594-1","article-title":"PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis","volume":"8","author":"Bravaccini","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2026.118779_bb0030","series-title":"Encyclopedia of Cancer","first-page":"3068","article-title":"Prostate-Specific Membrane Antigen","author":"Denmeade","year":"2011"},{"key":"10.1016\/j.bmc.2026.118779_bb0035","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2026.118779_bb0040","first-page":"2256","article-title":"Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases, Cancer","volume":"82","author":"Bostwick","year":"1998","journal-title":"Interdiscip Int J Am Cancer Soc"},{"key":"10.1016\/j.bmc.2026.118779_bb0045","series-title":"Prostate-specific membrane antigen biology in lethal prostate cancer and its therapeutic implications","author":"Sheehan","year":"2021"},{"key":"10.1016\/j.bmc.2026.118779_bb0050","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3390\/cancers12061367","article-title":"Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy","volume":"12","author":"Jones","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bmc.2026.118779_bb0055","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/jjco\/hyaa004","article-title":"Prostate-specific membrane antigen (PSMA)\u2013ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer","volume":"50","author":"Tateishi","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.bmc.2026.118779_bb0060","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.3390\/cancers13153904","article-title":"Science and Practice","volume":"13","author":"Mokoala","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bmc.2026.118779_bb0065","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.13946","article-title":"The utility of radiolabeled PSMA ligands for tumor imaging","volume":"99","author":"Shahrokhi","year":"2022","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmc.2026.118779_bb0070","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3390\/ijms23031158","article-title":"PSMA-Targeting Imaging and Theranostic Agents\u2014Current Status and Future Perspective","volume":"23","author":"Debnath","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2026.118779_bb0075","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1021\/acs.molpharmaceut.8b00499","article-title":"Effects of linker modification on tumor-to-kidney contrast of 68Ga-labeled PSMA-targeted imaging probes","volume":"15","author":"Kuo","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.bmc.2026.118779_bb0080","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1021\/acs.molpharmaceut.8b00720","article-title":"Enhancing treatment efficacy of 177Lu-PSMA-617 with the conjugation of an albumin-binding motif: preclinical dosimetry and endoradiotherapy studies","volume":"15","author":"Kuo","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.bmc.2026.118779_bb0085","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.2967\/jnumed.118.216598","article-title":"One-Step 18F-Labeling and Preclinical Evaluation of Prostate-Specific Membrane Antigen Trifluoroborate Probes for Cancer Imaging","volume":"60","author":"Kuo","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bmc.2026.118779_bb0090","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2967\/jnumed.120.250738","article-title":"177Lu-Labeled Albumin-Binder\u2013Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio","volume":"62","author":"Kuo","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bmc.2026.118779_bb0095","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.7150\/thno.76571","article-title":"What a difference a methylene makes: replacing Glu with Asp or Aad in the pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake","volume":"12","author":"Kuo","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bmc.2026.118779_bb0100","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1021\/acs.jmedchem.5b01268","article-title":"[18F] fluorobenzoyllysinepentanedioic acid carbamates: new scaffolds for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)","volume":"59","author":"Yang","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118779_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104304","article-title":"Structure-activity relationship studies of prostate-specific membrane antigen (PSMA) inhibitors derived from \u03b1-amino acid with (S)-or (R)-configuration at P1\u2032 region","volume":"104","author":"Kwon","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118779_bb0110","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bmc.2018.11.022","article-title":"Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors","volume":"27","author":"Barinka","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2026.118779_bb0115","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1055\/s-0029-1216983","article-title":"Straightforward total synthesis of 2-O-feruloyl-L-malate, 2-O-sinapoyl-L-malate and 2-O-5-hydroxyferuloyl-L-malate","volume":"2009","author":"Allais","year":"2009","journal-title":"Synthesis"},{"key":"10.1016\/j.bmc.2026.118779_bb0120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/00304947309356466","article-title":"On the preparation of \u03b1-ketoadipic acid","volume":"5","author":"Nelson","year":"1973","journal-title":"Org Prep Proced Int"},{"key":"10.1016\/j.bmc.2026.118779_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113752","article-title":"PSMA-targeted low-molecular double conjugates for diagnostics and therapy","volume":"225","author":"Petrov","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118779_bb0130","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/pros.23770","article-title":"PSMA expression in the Hi-Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool","volume":"79","author":"Simons","year":"2019","journal-title":"Prostate"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962600235X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962600235X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T08:36:34Z","timestamp":1788597394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096808962600235X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":26,"alternative-id":["S096808962600235X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118779","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSMA binding of carbamate-containing peptidomimetics influenced by side chain length and stereocenter configuration in preclinical prostate cancer model","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"118779"}}